Vedana Therapeutics

Vedana Therapeutics Secures $46M to Advance Anti-PACAP Migraine Therapies, Reshaping Treatment Landscape

Vedana Therapeutics secured $46 million Series A funding to advance anti-PACAP therapies for migraine prevention. This market entry targets the significant patient population unresponsive to CGRP inhibitors, leveraging a highly experienced leadership team. Decision-makers should assess Vedana's pipeline for future supply chain diversification and partnership opportunities in this evolving therapeutic area.